Once the universal screening policy for HER2-negative BC patients is adopted in China, it will prevent death and recurrence in a substantial number of patients with gBRCA mutations, with 0.3%, 0.9% and 1.5% of the population avoiding death 5, 10 and 20 years after treatment, respectively (Table S5). The gene discussed is ERBB2; the disease is breast cancer.